Date: 2015-06-01
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago
Company: Integragen (France)
Product: miR-31-3p biomarker
Action
mechanism: biomarker. IntegraGen obtained the exclusive license for the worldwide rights for the miR-31-3p biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris (AP-HP), all leading French academic institutions which, along with IntegraGen, are co-owners of the patent.
Disease: metastatic colorectal cancer (mCRC)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 1, 2015, IntegraGen announced the presentation of two studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting focusing on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with panitumumab or cetuximab. The data presented further validates previous studies which have documented that miR-31-3p expression in the primary tumor of mCRC patients is predictive of the effect of anti-EGFR therapy. “Evaluation of miR-31-3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer: analysis of patients from the PICCOLO trial.” This study analyzed miR-31-3p expression and associated outcomes in nearly 200 advanced colorectal cancer (aCRC) patients randomized to receive irinotecan or irinotecan plus panitumumab. Patients with lower miR-31-3p expression had significantly better overall and progression free survival (PFS). Patients with lower miR-31-3p expression had significantly better tumor response to panitumumab as measured by response rate and disease control. Patients with low and intermediate miR-31-3p expression had significant PFS benefit from panitumumab while patients with high expression did not. “Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.” This study evaluated if miR-31-3p and c-Met expression were associated with the more rapid disease progression seen with cetuximab in the New EPOC study. Expression of miR-31-3p and c-Met in primary tumor and matching CLRM were correlated in patients receiving chemotherapy alone (CT) but not in patients exposed to chemotherapy plus cetuximab (CTC). This work identified a subgroup of patients who derived significant benefit from cetuximab therapy. The loss of correlation between primary tumors and CRLM suggests that cetuximab may modulate miR-31-3p and c-Met expression and that these may be implicated in the mechanism by which earlier progression occurred in these patients.
